Skip to main content
Log in

Considerations for Good Pharmacovigilance Outsourcing Practices

  • Current Opinion
  • Published:
Pharmaceutical Medicine Aims and scope Submit manuscript

Abstract

Over the last approximately 20 years, the pharmaceutical industry has increasingly outsourced its research and development activities, including pharmacovigilance, with mixed results. To avoid significant failures, both clients and service providers should understand and openly discuss each other’s needs, avoiding the unrealistic expectations often elicited prior to signing a contract. Clients should ensure the outsourced project is adequately resourced in terms of time allocated to it and the skills and expertise of those who will do the actual work and training. They should recognise that quality can be compromised by cheapness and that a service provider’s physical distance and cultural difference are likely to interfere with communication and reciprocal understanding. Clients should always have a person in house who has a good knowledge of pharmacovigilance, so as to understand each activity in detail. This person should be involved in discussions with the service provider, assessing the support and information that the service provider requires, reviewing the vendor’s work, providing continuous feedback and avoiding confrontation by focussing on the needs and challenges the service provider is facing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Getz K, Lamberti MJ, Kaitin KI. Taking the pulse of strategic outsourcing relationships. Clin Ther. 2014;36(10):1349–55.

    Article  PubMed  Google Scholar 

  2. Research and Markets. Global pharmacovigilance market analysis and forecast, 2015–2022. BIS Res. September 2016.

  3. Edwards B, Wylie G. Outsourcing pharmacovigilance: perspectives of a global CRO, Chapter 7. In: Parexel International Corporation. Pharmacovigilance: effective safety surveillance strategies. Scrip reports 2002. London: PJB Publication Ltd. p. 217–55.

  4. Henderson L. The state of CRO and sponsor relationships. Appl Clin Trials. 2013;10:26–8.

    Google Scholar 

  5. Hughes J, Rayer E, Wadd K. Sponsor-CRO Collaboration Study. Boston: Vantage Partners LLC; 2013.

    Google Scholar 

  6. Heads of Medicines Agency, European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module I: pharmacovigilance systems and their quality systems. EMA/541760/2011; 2012.

  7. European Medicines Agency. Pharmacovigilance inspection policy for centralised procedures: medicinal products for human use. EMA/INS/PhV/163771/2013 Rev 1; 2013.

  8. Heads of Medicines Agency, European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module III: pharmacovigilance inspections. EMA/119871/2012 Rev 1; 2014.

  9. van Leeuwen BP, Prendergast C, Edwards B, et al. Can pharmacovigilance learn from the oil and gas industry, which has been outsourcing for over a century? Ther Innov Regul Sci. 2017;51(1):11–5.

    Article  Google Scholar 

  10. Kieran Trevett. GPvP inspections of contract service providers, August 2016 update. MHRA Inspectorate blog. https://mhrainspectorate.blog.gov.uk/2016/08/23/gpvp-inspections-of-contract-service-providers-august-2016-update/. Accessed 10 Jan 2017.

  11. Good Pharmacovigilance Practice Inspectorate, Medicines and Healthcare Products Regulatory Agency. Pharmacovigilance Inspection Metrics Report, April 2015–March 2016. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/550781/Pharmacovigilance_Inspection_Metrics_Report_2015-2016_FINAL.pdf. Accessed 10 Jan 2017.

  12. Edwards B. How should you safely outsource pharmacovigilance to an Indian CRO? Indian J Pharmacol. 2008;40(Suppl. 1):S25–7.

    Google Scholar 

Download references

Acknowledgements

The authors thank Mr. David Power, Helsinn Birex Pharmaceuticals, for reviewing the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Giovanni Furlan.

Ethics declarations

Funding

No funding was received for the preparation of this article.

Conflict of interest

Giovanni Furlan and Bert van Leeuwen are employees of a pharmaceutical company. Brian Edwards is an employee of a company providing pharmacovigilance services to pharmaceutical companies.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Furlan, G., van Leeuwen, B. & Edwards, B. Considerations for Good Pharmacovigilance Outsourcing Practices. Pharm Med 31, 75–80 (2017). https://doi.org/10.1007/s40290-017-0183-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40290-017-0183-9

Keywords

Navigation